Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Taegtmeyer, Heinrich; Karlstaedt, Anja

Taegtmeyer, Heinrich; Karlstaedt, Anja.

Afiliação

Taegtmeyer H; Department of Internal Medicine, Division of Cardiology, McGovern Medical School at The University of Texas Health Science Center at Houston.
Karlstaedt A; Department of Internal Medicine, Division of Cardiology, McGovern Medical School at The University of Texas Health Science Center at Houston.

Circulation ; 137(9): 986-987, 2018 02 27.

Article em En | MEDLINE | ID: mdl-29483178

Assuntos

Insuficiência Cardíaca; Inibidores do Transportador 2 de Sódio-Glicose; Canagliflozina; Glucose; Humanos; Sódio

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores do Transportador 2 de Sódio-Glicose / Insuficiência Cardíaca Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google